Clinicopathological implications of TIM3+ tumor-infiltrating lymphocytes and the miR-455-5p/Galectin-9 axis in skull base chordoma patients

Zhou, Jinpeng; Jiang, Yang; Zhang, Haiying; Chen, Lian; Luo, Peng; Li, Long; Zhao, Junshuang; Lv, Fei; Zou, Dan; Zhang, Ye

doi:10.1007/s00262-019-02349-1

Cited by 30 publications

(28 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, recent data have provided evidence for EGFR/Ras/ Mek signaling to control PD-L1 expression in cancers (39,40). Taken together, these outcomes further highlight the clinical significance of immune microenvironment in chordoma (21,41,42) and suggest a complete miR-574-3p/EGFR/Ras/Mek/PD-L1 signaling network involved in chordoma development. This finding deserves further investigation and may have implication for sole or combination immunotherapy approaches for chordoma treatment.…”

Section: Discussionmentioning

confidence: 71%

“…Preceding reports have suggested that the Enneking system as an indicator of anatomic features of tumors is not adequate to inform chordoma prognosis (21). Further, it has been determined that the immune microenvironment reflective of tumor bioimmunological properties plays a pivotal role in chordoma progression (20,21,41). Besides these data, recent studies have implied that radiological findings on magnetic resonance imaging are also related to chordoma outcome (43,44).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Development and Validation of a 6-miRNA Prognostic Signature in Spinal Chordoma

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

Development and Validation of a 6-miRNA Prognostic Signature in Spinal Chordoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…GSEA (http://www.broadinstitute.org/gsea/ index.jsp) was used to find enrichment of signal pathways between high and low RORA expression groups. Four online miRNA databases, Starbase (http://starbase.sysu.edu.cn), TargetScan (www.targetscan.org), microRNA (http://www.microrna.org/microrna/home.do), and miRDB (http://mirdb.org), were used to predict the possible miRNAs that targeted RORA by examining the RORA 3 0 -UTR with bioinformatics algorithms [32].…”

Section: Bioinformatics Analysismentioning

confidence: 99%

MiR-18a-downregulated RORA inhibits the proliferation and tumorigenesis of glioma using the TNF-α-mediated NF-κB signaling pathway

Jiang¹,

Zhou

Zhao

et al. 2020

EBioMedicine

Self Cite

View full text Add to dashboard Cite

Background: Glioma has a poor prognosis, and is the most common primary and lethal primary malignant tumor in the central nervous system. Retinoic acid receptor-related orphan receptor A (RORA) is a member of the ROR subfamily of orphan receptors and plays an anti-tumor role in several cancers. Methods: A cell viability assay, the Edu assay, neurosphere formation assay, and xenograft experiments were used to detect the proliferative abilities of glioma cell line, glioma stem cells (GSCs). Western blotting, ELISAs, and luciferase reporter assays were used to detect the presence of possible microRNAs. Findings: Our study found for the first time that RORA was expressed at low levels in gliomas, and was associated with a good prognosis. RORA overexpression inhibited the proliferation and tumorigenesis of glioma cell lines and GSCs via inhibiting the TNF-a mediated NF-kB signaling pathway. In addition, microRNA-18a had a promoting effect on gliomas, and was the possible reason for low RORA expression in gliomas. Interpretation: RORA may be a promising therapeutic target in the treatment of gliomas.

show abstract

“…These include e.g., miR-34, miR-15a/-16, miR-138a-5p, miR-149-3p, miR-455-5p miR-498, and miR-330 ( Table 5 ) [ 180 , 181 ]. Some of these miRNAs play an important role in hematologic malignancies and/or to negatively regulate the expression of TIM-3 and/or CD47 in hematopoietic cells [ 180 , 181 , 182 , 183 , 184 ]. Interestingly, miR-155, miR-34, and miR-133a target both TIM-3 and CD47.…”

Section: Therapeutic Possibilities Of Mirnas In Mds and Samlmentioning

confidence: 99%

Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins

Bauer

Vaxevanis

Heimer

et al. 2020

IJMS

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS), heterogeneous diseases of hematopoietic stem cells, exhibit a significant risk of progression to secondary acute myeloid leukemia (sAML) that are typically accompanied by MDS-related changes and therefore significantly differ to de novo acute myeloid leukemia (AML). Within these disorders, the spectrum of cytogenetic alterations and oncogenic mutations, the extent of a predisposing defective osteohematopoietic niche, and the irregularity of the tumor microenvironment is highly diverse. However, the exact underlying pathophysiological mechanisms resulting in hematopoietic failure in patients with MDS and sAML remain elusive. There is recent evidence that the post-transcriptional control of gene expression mediated by microRNAs (miRNAs), long noncoding RNAs, and/or RNA-binding proteins (RBPs) are key components in the pathogenic events of both diseases. In addition, an interplay between RBPs and miRNAs has been postulated in MDS and sAML. Although a plethora of miRNAs is aberrantly expressed in MDS and sAML, their expression pattern significantly depends on the cell type and on the molecular make-up of the sample, including chromosomal alterations and single nucleotide polymorphisms, which also reflects their role in disease progression and prediction. Decreased expression levels of miRNAs or RBPs preventing the maturation or inhibiting translation of genes involved in pathogenesis of both diseases were found. Therefore, this review will summarize the current knowledge regarding the heterogeneity of expression, function, and clinical relevance of miRNAs, its link to molecular abnormalities in MDS and sAML with specific focus on the interplay with RBPs, and the current treatment options. This information might improve the use of miRNAs and/or RBPs as prognostic markers and therapeutic targets for both malignancies.

show abstract

Clinicopathological implications of TIM3+ tumor-infiltrating lymphocytes and the miR-455-5p/Galectin-9 axis in skull base chordoma patients

Cited by 30 publications

References 62 publications

Development and Validation of a 6-miRNA Prognostic Signature in Spinal Chordoma

Development and Validation of a 6-miRNA Prognostic Signature in Spinal Chordoma

MiR-18a-downregulated RORA inhibits the proliferation and tumorigenesis of glioma using the TNF-α-mediated NF-κB signaling pathway

Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins

Contact Info

Product

Resources

About